Ruifeng Xue#, Zhiyan Liu#, Zhichao Tan#, Yujun Cui, Chujie Bai, Shu Li, Tian Gao, Lu Zhang, Xinyu Wang, Zhengfu Fan*, Jiayong Liu*. The efficacy and predictive value of 99mTc-rituximab for sentinel lymph node biopsy in acral melanoma patients.,World Journal of Surgical Oncology,Online ahead of print.

Honghong Liu, Rui Guo, Xiaojun Zhang, Huijuan Ji, Shuwei Sun, Shasha Sun, Jiayong Liu*, Zhi Yang* & Ruimin Wang*. Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study.,European Journal of Nuclear Medicine and Molecular Imaging,2026 Feb;53(3):1869-1880.

Honghong Liu, Rui Guo, Xiaojun Zhang, Huijuan Ji, Shuwei Sun, Shasha Sun, Jiayong Liu*, Zhi Yang* & Ruimin Wang*. Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study.,European Journal of Nuclear Medicine and Molecular Imaging,2026 Feb;53(3):1869-1880.

Honghong Liu, Rui Guo, Xiaojun Zhang, Huijuan Ji, Shuwei Sun, Shasha Sun, Jiayong Liu*, Zhi Yang* & Ruimin Wang*. Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study.,European Journal of Nuclear Medicine and Molecular Imaging,2026 Feb;53(3):1869-1880.

Jun Cao #, Zhichao Tan#, Enyu Yang, Qing ji, Meiyu Fang*, Jiayong Liu*. Clinical characteristics treatment outcomes of primary cardiac sarcoma:a retrospective analysis.,Cardio-Oncology,(2025) 11:109

张路，樊征夫，白楚杰，薛瑞峰，李舒，高天，王新宇，谭智超，谭学轶，刘佳勇*。聚乙二醇化脂质体多柔比星联合达卡巴嗪治疗平滑肌肉瘤的疗效分析。,中国骨与关节杂志,2025.14(11)

Gu Jin#,Dandan Zhao#,Baoming Wang#,Xuejiao Liu#,Quanyu Yang,Zhengchuang Liu,Qiong Yang,Jianhua Zhu,Jie Zhang,Wei Li,Xiaojuan Wang,Chunyang Wang,Tonghui Ma*,Jiayong Liu*. Superiority of targeted RNA sequencing for fusion detection and subtype diagnosis in Chinese sarcoma patients: a multicenter study.,Experimental Hematology & Oncology,2025 May 14; 14(1):70.

Tian Gao #,Xinyu He #,Junyi Wang#,Jiayong Liu#,Xiongbing Hu#,Chujie Bai#,Shenyi Yin,Yunfei Shi,Yanmin Wang,Zhichao Tan,Fang Cao,Shu Li,Yan-Jie Shi,Ruifeng Xue,Juan Li,Yang He,Jiaxin Li,Huinan Lu,Hanshuo Zhang,Lu Zhang,Zhiwei Fang,Xinyu Wang,Mengmeng Liu,Wenjun Fu,Lei Tang,Buqing Ye,Zhengfu Fan,Jianzhong Jeff Xi*,Cell Reports. Medicine,2025, Feb (28),101990. Online ahead of print.

Zhichao Tan#,Yan Wu#,Zhengfu Fan,Tian Gao,Sijuan Ding,Liang Han,Suxia Luo,Qingxia Fan,Jianhua Shi,Chujie Bai,Ruifeng Xue,Shu Li,Lu Zhang,Xinyu Wang,Ling Jia,Lixin Zhou,Binlei Liu,Jing Huang,Jiayong Liu*. Intratumoral oncolytic virus OH2 injection in patients with locally advanced or metastatic sarcoma: a phase 1/2 trial.,Journal of Immunotherapy of Cancer.,2025, Jan 16, 13(1):e010543.

Zhichao Tan#, Yan Wu#, Zhengfu Fan#,Tian Gao, Wei Guo, Chujie Bai, Ruifeng Xue, Shu Li, Lu Zhang, Xinyu Wang, Ling Jia, Jiayong Liu*. Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial.,Clinical Cancer Research,2024. Sep 16;30(24):5577-5583.

Jiayong Liu#,Xuan Wang#,Zhongwu Li#,Shunyu Gao#,Lili Mao,Jie Dai,Caili Li,Chuanliang Cui,Zhihong Chi,Xinan Sheng,Yumei Lai,Zhichao Tan,Bin Lian,Bixia Tang,Xieqiao Yan,Siming Li,Li Zhou,?Xiaoting Wei,Juan Li,Jun Guo,Lu Si*. Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial.,Signal Transduction and Targeted Therapy,2024, Nov 22; 9(1):318.

Qiuzhong Pan#,Desheng Weng#,Jiayong Liu#, Zhaosheng Han#,Yusheng Ou,Bushu Xu,Ruiqing Peng,Yi Que,Xizhi Wen,Jing Yang,Shi Zhong,Lun Zeng,Aiyuan Chen,Haiping Gong,Yanmei Lin,Jiewen Chen,Ke Ma,Johnson Y N Lau,Yi Li,Zhengfu Fan*,Xing Zhang*. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A?02:01 patients with advanced soft tissue sarcoma.,Cell Reports. Medicine,2023, Aug 15; 4(8):101133

Jiayong Liu*, Tian Gao*, Zhichao Tan*, Shu Li, Jie Xu, Chujie Bai, Ruifeng Xue, Lu Xie, Lu Zhang, Zhengfu Fan#, Wei Guo#. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.,Clinical Cancer Research.,2022. 28(16):3473-3479

Chaohu Pan*, Qiaomei Cai*, Xiaorong Li, Lili Li, Liping Yang, Yu Chen, Junxiao Liu, Wancheng Liu, Meiling Gao, Tianqi Sui, Xiaoyang Wang, Huiming Fan, Jiayin Ruan, Yueyue Shi, Saihua Chen, Lucy S Cheng, Jiayong Liu #, Heng Yang #, Genhong Cheng#. Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1.,Cellular & Molecular Immunology,2022. 19(4):516-526

Zhichao Tan*, Jiayong Liu*#, Ruifeng Xue?, Zhengfu Fan, Chujie Bai, Shu Li, Tian Gao, Lu Zhang and Xinyu Wang. Clinical features and therapeutic outcomes of alveolar soft part sarcoma in children: A single-center, retrospective study.,Frontiers in Oncology,12:1019911. doi: 10.3389/fonc.2022.1019911.

Yuxing Huang*, Jing Su*, Jiayong Liu*, Xin Yi, Fang Zhou, Jiaran Zhang, Jiaxiang Wang, Xuan Meng, Lu Si #, Congying Wu #. YAP Activation in Promoting Negative Durotaxis and Acral Melanoma Progression.,Cells,2022. 11(22):3543. doi: 10.3390/cells11223543.

Jiayong Liu* #, Peijie Liu, Fuyu Gong, Youhui Tian, Xiaochen Zhao. Case Report: A PD-L1-Positive Patient With Pleomorphic Rhabdomyosarcoma Achieving an Impressive Response to Immunotherapy.,Frontiers in Immunology.,2022. 17;13:815598

Zhichao Tan, Xinyu Wang#, Jiayong Liu# *, Zhengfu Fan, Tian Gao, Chujie Bai, Ruifeng Xue, Shu Li, Lu Zhang. Efficacy of PD-1 inhibitors combined with pegylated liposomal doxorubicin and dacarbazine compared with liposomal doxorubicin and dacarbazine in advanced leiomyosarcoma patients：a retrospective, single-institutional cohort study.,Annals of Translational Medicine.,2022,10(18):1000.

Jiayong Liu* #, Zhichao Tan*, Ruifeng Xue*, Zhengfu Fan, Chujie Bai, Shu Li, Tian Gao, Lu Zhang, Zhiwei Fang, Lu Si #. The efficacy of Tc-99m- rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients.,Annals of Translational Medicine,2022. 10(2):95. doi: 10.21037/atm-21-6890.

以融合基因新生抗原作为腺泡状软组织肉瘤细胞治疗新靶点的可行性研究, 课题负责人, 2025.7.1～2028.6.30, 北京市自然科学基金联合重点项目（100w）

原发性心脏肉瘤：化疗联合免疫治疗的疗效探索及通过多组学方法对患者预后的进行预测价值, 课题负责人, 2025.1.1～2027.12.31, 北京市属医院 科研培育计划项目（10w)

软组织肉瘤：新辅助大分割放疗联合化疗的治疗可行性及多组学结合的人工智能疗效预测模型构建, 课题负责人, 2025.1.1～2027.12.31, 北京大学世纪金源“腾云临床研究专项”（50w）

基于配对样本的腺泡状软组织肉瘤免疫治疗应答与耐药机制的单细胞动态图谱研究（10.4w）, 课题负责人, 2026.1.1～2026.12.31, 北京大学肿瘤医院院内学科发展项目（10.4W）

艾帕洛利托沃瑞丽单抗治疗晚期转移或不可切除腺泡状软组织肉瘤：一项单臂、前瞻性、II期临床研究, 课题负责人, 2026.3.1～2029.3.1, 北京大学肿瘤医院临床研究基金（50w)

脂质体多柔比星联合达卡巴嗪一线化疗后序贯替莫唑胺维持治疗晚期或不可切除的平滑肌肉瘤的有效性与安全性研究, 课题负责人, 2026.1.1～2027.12.31, 吴阶平医学基金会科研专项资助基金(10w)

三级淋巴结构对腺泡状软组织肉瘤免疫治疗疗效预测作用的研究, 课题负责人, 2025.5.1～2026.12.31, 中国医药卫生事业发展基金会(10w)

作为PI主持多项注册类及IIT临床研究，其中目前仍在研的项目包括： 注册类试验：1、AN4005治疗晚期肿瘤患者的开放、多中心、I期研究；2、一项评估DB-1311在晚期/转移性实体瘤受试者中的安全性、耐受性、药代动力学和初步抗肿瘤活性的I/IIa期、多中心、开放性、首次人体研究。 IIT项目：1、评估IBI363治疗晚期转移或不可切除软组织肉瘤（Ⅳ期）受试者的安全性、耐受性和有效性的Ⅰ期临床研究；2、评估【225Ac】Ac-FAPI-XT注射液在FAP表达阳性的晚期实体瘤患者中安全性、耐受性、辐射剂量学特征以及初步有效性的临床研究；3、脂质体多柔比星+达卡巴嗪联合特瑞普利单抗治疗不可切除或转移性心脏肉瘤的研究；4、阿法替尼、替莫唑胺联合卡瑞丽珠单抗治疗晚期不可切除或转移性透明细胞肉瘤的有效性及安全性研究；5、口服替莫唑胺用于平滑肌肉瘤蒽环类化疗结疗后维持治疗的疗效研究。, 课题负责人, 2024.1.10～2026.12.31, 临床试验